Xenon Pharmaceuticals halted enrollment in phase 3 major depressive disorder studies of azetukalner after reports of neuropsychiatric adverse events emerged in the broader patient population. Recruitment for patients not yet enrolled is stopped, while studies continue for participants already enrolled and the readout is expected in early 2027.